Evidence map›Paper›PMID 31756900›Full record

ReviewInternational journal of molecular sciences2019

Targeting Tumor Endothelial Cells with Nanoparticles.

Yu Sakurai, Hidetaka Akita, Hideyoshi Harashima

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yu SakuraiGraduate School of Pharmaceutical Sciences, Chiba University, Chiba, 260-8675, Chiba, Japan.
Hidetaka AkitaGraduate School of Pharmaceutical Sciences, Chiba University, Chiba, 260-8675, Chiba, Japan.
Hideyoshi HarashimaFaculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, 060-0812, Hokkaido, Japan.

Funding

Core Research for Evolutional Science and Technology JPMJCR17H1Japan Society for the Promotion of Science 18K18351
6 · The paper itself

Abstract

Because angiogenesis is a major contributor to cancer progression and metastasis, it is an attractive target for cancer therapy. Although a diverse number of small compounds for anti-angiogenic therapy have been developed, severe adverse effects commonly occur, since small compounds can affect not only tumor endothelial cells (TECs), but also normal endothelial cells. This low selectivity for TECs has motivated researchers to develop alternate types of drug delivery systems (DDSs). In this review, we summarize the current state of knowledge concerning the delivery of nano DDSs to TECs. Their payloads range from small compounds to nucleic acids. Perspectives regarding new therapeutic targets are also mentioned.

Indexed as

AnimalsAntineoplastic AgentsDrug CarriersEndothelial CellsHumansNanoparticlesNeoplasmsNeovascularization, PathologicAntineoplastic AgentsDrug Carriersanti-angiogenic therapydrug delivery systemnanoparticlesnucleic acidstumor endothelial cells

Identifiers

PMID31756900
PMCPMC6928777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.